DGAP-News: MeVis Medical Solutions confirms preliminary

MeVis Medical Solutions AG / Final Results

30.04.2009 

Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

MeVis Group remains on growth track in spite of difficult market conditions

* Sales revenues up by 37%, to reach EUR 10.8 million (previous year: EUR
7.9 million)
* EBIT amounting to EUR 0.7 million (previous year: EUR 0.8 million)
* Net financial result increases to EUR 2 million (previous year:  EUR 0.3
million)
* Consolidated net profit for the year reaches EUR 2.1 million (previous
year: EUR 0.1 million)
* Earnings per share amount to EUR 1.21 (previous year: EUR 0.17) 

Bremen, April 30, 2009 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a
software specialist for image-based medicine, confirms its preliminary
figures released in February for fiscal 2008.

Accordingly, in spite of a weak fourth quarter, Group sales amounted to
approx. EUR 10.8 million for the last fiscal year. While sales generated in
Europe were up by 11%, revenues in the U.S. region increased by 40%, to
reach approx. EUR 9.6 million.

Sales in the 'Digital Mammography' segment were bolstered by 25%, to
approx. EUR 6.8 million. With a share of 63%, this segment remains the
Group's main growth driver for sales. It comprises the extensive
'BreastCare' applications from the MeVis Group for early detection and
diagnosis of breast cancer, which are successfully distributed worldwide
via the industry partners Hologic, Inc. and Siemens AG. Following the
carve-out under company law from the joint venture operated with Siemens,
since November 1, 2008 business with the industry partner Hologic has been
fully consolidated in this segment.

In the segment 'Other Diagnostics', sales were boosted by 69%, to approx.
EUR 4 million, via industry partners within the scope of OEM distribution
and though clinics as end customers for specialized services. This segment
comprises the software application for the world's leading diagnostic
workstation for contrast-enhanced magnetic resonance imaging of the breast,
from industry partner Invivo, other sales-generating software applications
for digital radiology and services in the field of pre-operative planning
of surgery. The segment also extends to include the development of new
software applications in the area of lung, neuro, prostate and colon. These
new products generated little or no sales revenues as yet in fiscal 2008.

EBIT, amounting to roughly EUR 0.7 million, was impacted in particular by
the 83% increase in personnel expenditure, amounting to approximately EUR
7.7 million (previous year: EUR 4.2 million). The size of the workforce
doubled on an annual average, to reach 181. The initial capitalization of
development expenses in accordance with IAS 38 produced gains of about EUR
1.9 million in fiscal 2008.

Currency translation gains and losses are no longer reported within EBIT,
as was the case in the previous year, but within net financial result. 'In
the past, group operating results were exposed to daily fluctuating market
valuations of currency hedge transactions', says Christian H. Seefeldt, new
Chief Financial Officer of MeVis Medical Solutions. 'As a result, both
operational control and the true value of EBIT were substantially
impaired.' Without this policy change, the MeVis Group would have reported
EBIT of approx. EUR 1.4 million for fiscal 2008 (previous year: EUR 0.5
million).

The change in value of financial instruments for currency hedging purposes
and currency translation gains, at approx. EUR 1.3 million (previous year: 
EUR 0.3 million) contributed roughly EUR 2.0 million to net financial
income (previous year:  EUR 0.3 million). Consolidated net profit for the
year after taxes thus rose to roughly EUR 2.1 million (previous year: EUR
0.1 million). This corresponds to earnings per share of EUR 1.21 (year-ago
period: EUR 0.17).

'Due to the ongoing substantial uncertainties prevailing in the U.S.
market, a reliable forecast for the current fiscal year is not possible',
says Dr. Carl J.G. Evertsz, CEO of MeVis Medical Solutions. 'However, the
effective impact for the entire fiscal year 2009 of the full consolidation
of the Hologic division in the 'Digital Mammography' segment and the
gradual market launch of new products, such as diagnostic software for the
automated ultrasound breast volume scanner ACUSON S2000 (ABVS) from Siemens
should lead to a substantial surge in revenues in 2009 and, as of the
second half-year, also to improved earnings.'

The full annual report for 2008 will be available shortly for download from
the company's website.
DGAP 30.04.2009 
---------------------------------------------------------------------------
Language:     English
Issuer:       MeVis Medical Solutions AG
              Universitätsallee 29
              28359 Bremen
              Deutschland
Phone:        +49 421 330 74-0
Fax:          +49 421 330 74-50
E-mail:       ir@mevis.de
Internet:     http://www.mevis.de
ISIN:         DE000A0LBFE4
WKN:          A0LBFE
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, München, Düsseldorf, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: MeVis Medical Solutions confirms preliminary figures for fiscal 2008:
